Leerink Partnrs Lowers Earnings Estimates for 10x Genomics

10x Genomics, Inc. (NASDAQ:TXG) – Leerink Partnrs dropped their Q1 2025 earnings per share estimates for 10x Genomics in a research report issued to clients and investors on Thursday, February 13th. Leerink Partnrs analyst P. Souda now anticipates that the company will post earnings of ($0.54) per share for the quarter, down from their previous estimate of ($0.42). Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for 10x Genomics’ current full-year earnings is ($1.43) per share. Leerink Partnrs also issued estimates for 10x Genomics’ Q2 2025 earnings at ($0.43) EPS, Q2 2025 earnings at ($0.43) EPS, Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($1.49) EPS, FY2025 earnings at ($1.49) EPS, Q2 2026 earnings at ($0.29) EPS, Q3 2026 earnings at ($0.29) EPS, Q3 2026 earnings at ($0.29) EPS, Q4 2026 earnings at ($0.20) EPS, FY2026 earnings at ($1.13) EPS, FY2026 earnings at ($1.13) EPS, FY2027 earnings at ($0.82) EPS and FY2027 earnings at ($0.82) EPS.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings data on Wednesday, February 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 28.93% and a negative return on equity of 25.07%.

Several other equities research analysts have also recently weighed in on TXG. Leerink Partners cut 10x Genomics from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $25.00 to $12.00 in a report on Thursday. JPMorgan Chase & Co. reduced their price objective on 10x Genomics from $14.00 to $12.00 and set a “neutral” rating for the company in a research report on Thursday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 10x Genomics in a research report on Saturday, February 1st. Citigroup cut their target price on 10x Genomics from $23.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday. Finally, Barclays dropped their price target on 10x Genomics from $19.00 to $18.00 and set an “overweight” rating on the stock in a research note on Monday, February 10th. One analyst has rated the stock with a sell rating, nine have given a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $20.57.

10x Genomics Trading Up 3.1 %

TXG opened at $12.31 on Monday. The stock has a market capitalization of $1.49 billion, a P/E ratio of -8.05 and a beta of 1.85. 10x Genomics has a 12-month low of $10.80 and a 12-month high of $51.22. The stock has a 50-day moving average price of $14.68 and a 200-day moving average price of $17.33.

Institutional Investors Weigh In On 10x Genomics

A number of hedge funds have recently bought and sold shares of TXG. Signaturefd LLC grew its stake in shares of 10x Genomics by 424.6% in the 4th quarter. Signaturefd LLC now owns 1,794 shares of the company’s stock valued at $26,000 after purchasing an additional 1,452 shares during the last quarter. Capital Performance Advisors LLP acquired a new position in 10x Genomics during the third quarter worth $35,000. Blue Trust Inc. raised its holdings in shares of 10x Genomics by 136.5% in the third quarter. Blue Trust Inc. now owns 1,776 shares of the company’s stock worth $40,000 after acquiring an additional 1,025 shares during the last quarter. Sound Income Strategies LLC raised its holdings in shares of 10x Genomics by 65.2% in the fourth quarter. Sound Income Strategies LLC now owns 3,370 shares of the company’s stock worth $48,000 after acquiring an additional 1,330 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of 10x Genomics in the fourth quarter worth $52,000. Institutional investors and hedge funds own 84.68% of the company’s stock.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.